Spinal Cord Injury News and Research

RSS

A spinal cord injury usually begins with a sudden, traumatic blow to the spine that fractures or dislocates vertebrae. The damage begins at the moment of injury when displaced bone fragments, disc material, or ligaments bruise or tear into spinal cord tissue. Most injuries to the spinal cord don't completely sever it. Instead, an injury is more likely to cause fractures and compression of the vertebrae, which then crush and destroy the axons, extensions of nerve cells that carry signals up and down the spinal cord between the brain and the rest of the body. An injury to the spinal cord can damage a few, many, or almost all of these axons. Some injuries will allow almost complete recovery. Others will result in complete paralysis.

FRC expresses disappointment over federal taxpayer funding of embryonic stem cell research

Family Research Council expressed disappointment in a 2-1 split decision today by the U.S. Court of Appeals in Washington, D.C. that allows the Obama administration to continue federal taxpayer funding of embryonic stem cell research.

30 Apr 2011

Invivo Therapeutics' Chief Science Officer selected as recipient of 2011 Apple Award

InVivo Therapeutics, a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries, today announced that Chief Science Officer Dr. Christopher Pritchard, Ph.D., has been selected as the 2011 recipient of the American Spinal Injury Association's prestigious Apple Award.

30 Apr 2011

Shielding body protects brain from “shell shocking” blast injuries

Stronger and tougher body armor to shield the chest, abdomen and back may be just what soldiers fighting in the Afghanistan and Iraq wars need to better protect their brains from mild injuries tied to so-called “shell shock,” results of a Johns Hopkins study in mice suggest. Such mild trauma, resulting from the initial shock of exploding mines, grenades and improvised explosive devices (IEDs) now accounts for more than 80 percent of all brain injuries among U.S. troops. Some 160,000 American veteran men and women are estimated to have sustained this kind of trauma.

29 Apr 2011

Experts to present stem cell therapies for neurological disorders at Cedars-Sinai conference

Experts from stem cell programs at respected research centers around the country will present information at an April 30 conference on stem cell therapy for neurological disorders, hosted by the Department of Neurosurgery at Cedars-Sinai Medical Center in collaboration with the Genetics Policy Institute of Wellington, Fla.

29 Apr 2011

Kadmon Pharmaceuticals and Nano Terra announce worldwide licensing agreement

Kadmon Pharmaceuticals LLC, and Nano Terra, Inc., today announced that they have entered into an agreement under which Kadmon has been granted a perpetual, worldwide exclusive license to three novel, clinical-stage product candidates owned by Nano Terra as well as rights to Nano Terra’s drug discovery platform, Pharmacomer™ Technology. The product candidates and technology platform will be transferred to a newly formed joint venture, NT Life Sciences (“NT Life”), co-owned by Kadmon and Nano Terra, which will act as the licensor and recipient of any licensing or royalty fees subject to the agreement. Terms of the agreement were not disclosed.

25 Apr 2011

XenoPort files SPA with FDA for arbaclofen placarbil Phase 3 trial in multiple sclerosis

XenoPort, Inc. announced today that it had reached agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment for a pivotal Phase 3 clinical trial of arbaclofen placarbil, previously known as XP19986, as a potential treatment of spasticity in multiple sclerosis patients.

25 Apr 2011

Nano Terra, Kadmon sign deal to license novel product candidates

25 Apr 2011

Neuralstem signs MoU with BaYi Brain Hospital for ischemic stroke program in China

Neuralstem, Inc. (NYSE Amex: CUR) announced it has signed a Memorandum of Understanding with BaYi Brain Hospital in Beijing, China.

21 Apr 2011

Combination therapy restores skilled use of limb in rodent model

After the acute treatment window closes, the only effective treatment for stroke is physical/occupational therapy. Now scientists from Children's Hospital Boston report a two-pronged molecular therapy that leads to significant recovery of skilled motor function in a rat model of stroke.

20 Apr 2011

Acorda receives patent for AMPYRA tablets to improve walking in MS patients

Acorda Therapeutics, Inc. today announced that the United States Patent and Trademark Office has allowed U.S. Patent Application No. 11/010,828 entitled "Sustained Release Aminopyridine Composition."

20 Apr 2011

First bypass surgery to restore lost brain tissue performed at Krembil Neuroscience Centre

Neurosurgeons at the Krembil Neuroscience Centre, Toronto Western Hospital, have for the first time, initiated the restoration of lost brain tissue through brain bypass surgery in patients where blood flow to the brain is impaired by cerebrovascular disease. The study, which involved 29 patients, was published online in the journal Stroke.

19 Apr 2011

Insight into Cervical Spondylotic Myelopathy

Researchers at the Krembil Neuroscience Centre, Toronto Western Hospital have identified a cell receptor, which is responsible for cell death in the spinal cord in a condition called Cervical Spondylotic Myelopathy.

15 Apr 2011

Viewpoints abound on impact of Ryan plan, government showdown

If the federal government shuts down at midnight on Friday — which seems likely unless negotiations take a sudden turn toward rationality — it will not be because of disagreements over spending. It will be because Republicans are refusing to budge on these ideological demands: No federal financing for Planned Parenthood. ... No local financing for abortion services in the District of Columbia. ... No funds for health care reform.

8 Apr 2011

Neuralstem to present HSSC Phase I trial data in amyotrophic lateral sclerosis at AAN meeting

Neuralstem, Inc. announced that the Phase I safety trial of its human spinal cord stem cells in amyotrophic lateral sclerosis is the subject of three presentations at the American Academy of Neurology Annual Meeting, April 9-16th, in Honolulu, HI.

7 Apr 2011

Stem Cell Action Coalition issues urgent appeal to Minnesota Governor for SCNT research

The Stem Cell Action Coalition issued an urgent appeal to Minnesota Governor Mark Dayton to veto any legislation that contains any impediment to lawful embryonic stem cell research in the state.

2 Apr 2011

HLS receives state permission to build new rehabilitation hospital in Ocala, Florida

HealthSouth Corporation today announced that it has received permission from the state to proceed with building a comprehensive physical rehabilitation hospital in Ocala, Fla.

1 Apr 2011

Study identifies unique adult animal stem cells that can turn into neurons

A group of scientists at Marshall University is conducting research that may someday lead to new treatments for repair of the central nervous system.

25 Mar 2011

UC Berkeley, UCSF partner to help develop neural prostheses for brain repair

Neuroscientists and engineers at UCSF and UC Berkeley have joined forces to help pioneer a new frontier of brain repair - the development of devices that would allow patients with such conditions as stroke, spinal cord injury, traumatic brain injury and Lou Gehrig's disease to control prosthetics through thoughts alone.

25 Mar 2011

BrainStorm provides review of recent accomplishments for shareholders, investors

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies and therapeutics, today provided a review of recent accomplishments for shareholders and investors.

25 Mar 2011

XenoPort reports preliminary top-line results from arbaclofen placarbil Phase 2b clinical trial in GERD

XenoPort, Inc. announced today preliminary top-line results from a Phase 2b clinical trial of arbaclofen placarbil (also known as AP) as adjunctive therapy in patients with gastroesophageal reflux disease (GERD) who do not experience complete relief of GERD symptoms while being treated with proton pump inhibitors (PPI).

21 Mar 2011

Spinal Cord Injury News and Research

Further Reading

FRC expresses disappointment over federal taxpayer funding of embryonic stem cell research

Invivo Therapeutics' Chief Science Officer selected as recipient of 2011 Apple Award

Shielding body protects brain from “shell shocking” blast injuries

Experts to present stem cell therapies for neurological disorders at Cedars-Sinai conference

Kadmon Pharmaceuticals and Nano Terra announce worldwide licensing agreement

XenoPort files SPA with FDA for arbaclofen placarbil Phase 3 trial in multiple sclerosis

Nano Terra, Kadmon sign deal to license novel product candidates

Neuralstem signs MoU with BaYi Brain Hospital for ischemic stroke program in China

Combination therapy restores skilled use of limb in rodent model

Acorda receives patent for AMPYRA tablets to improve walking in MS patients

First bypass surgery to restore lost brain tissue performed at Krembil Neuroscience Centre

Insight into Cervical Spondylotic Myelopathy

Viewpoints abound on impact of Ryan plan, government showdown

Neuralstem to present HSSC Phase I trial data in amyotrophic lateral sclerosis at AAN meeting

Stem Cell Action Coalition issues urgent appeal to Minnesota Governor for SCNT research

HLS receives state permission to build new rehabilitation hospital in Ocala, Florida

Study identifies unique adult animal stem cells that can turn into neurons

UC Berkeley, UCSF partner to help develop neural prostheses for brain repair

BrainStorm provides review of recent accomplishments for shareholders, investors

XenoPort reports preliminary top-line results from arbaclofen placarbil Phase 2b clinical trial in GERD

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News